ClinicalTrials.gg
Not yet recruitingNCT07725458PEPUpdated Jul 27, 2026

Patient Empowerment Project (PEP) Study

An observational study in Infertility and Mental Health, sponsored by Inception Fertility Research Institute, LLC. Not yet recruiting at 2 sites in United States. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Inception Fertility Research Institute, LLC · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Sex
All
01

Study summary

The Patient Empowerment Project (PEP) will be integrated into the intake process at a fertility clinic to prepare clinical staff for any patient sensitivities or preferences and provide extra support if needed. The study will evaluate if the PEP increases patient retention and patient satisfaction scores.

02

Conditions studied

  • Infertility
  • Mental Health

Keywords

  • Infertility
  • Mental health
  • Assistive Reproductive Technology
03

In context

Infertility

2,085 studies on the registry are indexed under Infertility; 357 are open to participants now.

This study's planned enrollment of 100 is below the median of 200 across 592 observational studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Inception Fertility Research Institute, LLC is the lead sponsor of 12 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients seeking fertility treatment at participating clinics

Eligibility criteria

Patients seeking fertility treatment at participating clinics

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Intervention

    The PEP questionnaire will be implemented at the intervention clinic and staff will receive training to address responses.

    Behavioral: Patient Empowerment Program (PEP)

  • Control

    Patients at the Control clinic will receive standard of care with no changes or additional questionnaires.

Interventions

  • BehavioralPatient Empowerment Program (PEP)

    The clinic staff will receive PEP training from a licensed psychologist (the PI). PEP will be implemented, starting after training is complete. The PEP Introduction and the PEP Questionnaire will be included in the New Patient Packet. The patient will complete the PEP questionnaire as they complete their new patient intake forms. Clinic staff will tailor their approach to the patient based on the patient's responses to the questionnaire.

06

What researchers measure

Primary outcomes

  1. Patient Satisfaction

    Standard patient satisfaction surveys will be collected at regular intervals throughout the study period

    Time frame: New Patient consultation to 6 months later

  2. Patient Retention Rate

    Patient retention is measured by the percentage of patients who attended a new patient consult and moved forward with treatment.

    Time frame: New patient consultation to 6 months later

07

Study locations

2 sites
  • The Reproductive Medicine Group
    Tampa, Florida 33609, United States
  • Aspire Fertility Dallas
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.

Of 242 observational studies under Infertility, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 100. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Jul 24, 2026
StartEst.
Aug 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07725458
Responsible party
Sponsor
First posted
Jul 24, 2026
Start date
Aug 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Jul 27, 2026

Study contacts

Laurel Anderson, BS
Contact
landerson@inceptionllc.com
3463621476

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion